Refine Search Results
Search Results Table
| Result Summary | |||
|---|---|---|---|
| S.4 |
449
|
Gómez, Adam |
GLP-1 Coverage
further, that the commission shall maintain GLP-1 coverage for obesity”; and in said ... |
| H.5500 |
1490
|
Turco, Jeffrey Rosario |
GLP-1 Equity Amendment
moves to amend the bill by added at the end a new section: Section XX Chapter 32A of ... reimbursement for glucagon-like peptide-1 (GLP-1) receptor agonist prescriptions that are ... |
| H.4530 |
7
|
Soter, Michael J. |
Coverage for GLP-1's for GIC Employees
by adding the following two sections: “SECTION XXX ... Chapter 32A of the General Laws is ... glucagon-like peptide-1 receptor agonist medications (GLP-1s) that have been approved by ... |
| S.4 |
492
(Redraft)
|
Friedman, Cindy F. |
GLP-1 Coverage Loss Study
by striking out the following words:- “and provided further, that not later than February 5, 2027, the commission shall submit a report to the joint committee on health care ... |
| H.5500 |
1693
|
Decker, Marjorie C. |
Maintaining Patient Access to Care
maintain coverage for glucagon-like peptide-1 (GLP-1) receptor agonist medications for the ... |
| H.5500 |
897
|
Lipper-Garabedian, Kate |
Protecting 340B Providers in the Medicaid Program
moves to amend the bill by adding the following section: “SECTION XXXX ... or (ii) is one of the seven GLP-1 Agonist drugs designated by the executive office that is ... |
| S.4 |
501
|
Payano, Pavel |
Protecting 340B Providers in the Medicaid Program
by inserting after section __ the following section:- "SECTION ... or (ii) is one of the seven GLP-1 Agonist drugs designated by the executive office that is ... |
| S.3 |
555
|
Crighton, Brendan P. |
340B Drug Pricing
by inserting after section __ the following section:- SECTION XX ... or (ii) is one of the seven GLP-1 Agonist drugs designated by the executive office that is ... |
| H.4000 |
635
|
Lipper-Garabedian, Kate |
340B Drug Pricing
moves to amend the bill by adding the following section: SECTION XXX ... or (ii) is one of the seven GLP-1 Agonist drugs designated by the executive office that is ... |